{"id":"W2600193304","doi":"10.1200/jco.2007.25.18_suppl.7611","title":"A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T790M; Internal medicine; Lapatinib; Clinical endpoint; KRAS; Population; Lung cancer; non-small cell lung cancer (NSCLC); Gastroenterology; Phases of clinical research; Oncology; Cancer; Chemotherapy; Surgery; Clinical trial; Breast cancer; Trastuzumab; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001838607,0.00189402,0.002148359,0.000463398,0.0003982268,0.0009237689,0.000937747,0.001643913,0.006018981],"category_scores_gemma":[0.001309766,0.0006881905,0.001280096,0.0004086085,0.001068771,0.001181078,0.0004691542,0.00315006,0.001272396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007125058,"about_ca_system_score_gemma":0.001338879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000584782,"about_ca_topic_score_gemma":0.001539801,"domain_scores_codex":[0.9994131,0.0003153094,0.00002621212,0.0001175677,0.00003167825,0.00009613827],"domain_scores_gemma":[0.9989243,0.000216826,0.0001951502,0.0000850552,0.00005595377,0.0005226887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9448336,0.02660685,0.001476571,0.0002501456,0.000393247,0.00005155654,0.00009098635,0.0005353852,0.007504499,0.000108704,0.0007828568,0.01736561],"study_design_scores_gemma":[0.7421155,0.2541424,0.002100104,0.00001063393,0.0001408352,0.00004679865,0.00002326338,0.0003412943,0.0005432754,0.00007524961,0.0004499029,0.00001074319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921756,0.001060001,0.000540247,0.0004401713,0.0002578351,0.003242746,0.0007952576,0.00008859281,0.001399563],"genre_scores_gemma":[0.983979,0.001232583,0.001915041,0.00102691,0.0004528489,0.005477296,0.002124129,0.00003533487,0.003756753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006018981,"threshold_uncertainty_score":0.02013546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0857046195069171,"score_gpt":0.4627108171647395,"score_spread":0.3770061976578224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}